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Abstract
Crescentic glomerulonephritis (CRGN) is a major cause of rapidly progressive renal failure for
which the underlying genetic basis is unknown. WKY rats show marked susceptibility to CRGN,
while Lewis rats are resistant. Glomerular injury and crescent formation are macrophage-
dependent and mainly explained by seven quantitative trait loci (Crgn1-7). Here, we used
microarray analysis in basal and lipopolysaccharide (LPS)-stimulated macrophages to identify
genes that reside on pathways predisposing WKY rats to CRGN. We detected 97 novel positional
candidates for the uncharacterised Crgn3-7. We identified 10 additional secondary effector genes
with profound differences in expression between the two strains (>5-fold change, <1% False
Discovery Rate) for basal and LPS-stimulated macrophages. Moreover, we identified 8 genes with
differentially expressed alternatively spliced isoforms, by using an in depth analysis at probe-level
that allowed us to discard false positives due to polymorphisms between the two rat strains.
Pathway analysis identified several common linked pathways, enriched for differentially
expressed genes, which affect macrophage activation. In summary, our results identify distinct
macrophage transcriptome profiles between two rat strains that differ in susceptibility to
glomerulonephritis, provide novel positional candidates for Crgn3-7, and define groups of genes
that play a significant role in differential regulation of macrophage activity.
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Introduction
Crescentic glomerulonephritis (CRGN) is a major cause of rapidly progressive renal failure
for which the underlying genetic basis is largely unknown 1. The Wistar-Kyoto (WKY) rat
shows marked susceptibility to CRGN, as administration of a small dose of nephrotoxic
serum (NTS), that is subnephritogenic in other strains, leads to rapid onset of nephrotoxic
nephritis (NTN). In WKY rats, NTN is characterised by the development of albuminuria by
day 4, crescent formation in the majority of glomeruli by day 11 and progression to severe
scarring, that is characteristic of CRGN, with renal failure by 6 weeks 2. Monocytes/
macrophages and CD8+ cells are the major cell types in the glomerular infiltrate, detected as
early as 2.5 hours after injection of NTS, and reaching a maximal number between days 4
and 8 2. The model is highly reproducible and the histology closely resembles that seen in
human glomerulonephritis. In contrast Lewis (LEW) rats, which share the same MHC
haplotype (RT1-l), develop only mild glomerular hypercellularity with no crescents after
administration of the same dose of NTS 3.
In WKY rats, macrophage depletion studies 4 have shown that glomerular injury in CRGN
is macrophage dependent. This suggests at least in part, shared pathophysiology with human
CRGN, where macrophage accumulation correlates with the degree of histological and
functional injury 5-7. Furthermore, bone marrow-derived macrophages (BMDMs) from
WKY rats show a number of phenotypic differences compared with those from LEW rats
including enhanced antibody-dependent cytotoxicity, Fc receptor-mediated phagocytosis
and Fc-receptor-dependent oxidative burst, as well as increased inducible nitric oxide
synthase gene (Nos2) expression upon lipopolysaccharide (LPS) stimulation 3,8. However,
bone marrow and kidney transplantation studies between WKY and LEW rats show that, in
addition to circulating cells, genetic susceptibility to CRGN is also partly dependent on
intrinsic factors within the kidney itself 9,10.
In previous studies, we carried out a genome-wide linkage analysis of an F2 population
derived from WKY and LEW rats and mapped seven CRGN quantitative trait loci (QTL)
(Crgn1-7) linked to crescent formation, proteinuria or macrophage infiltration 3. The two
most significant linkage peaks, with lod score over 8, were on chromosomes 13 (Crgn1) and
16 (Crgn2). By a combination of expression studies, fine mapping and functional assays, we
identified deletion of an Fc receptor gene, Fcgr3-rs, as a cause of macrophage over-activity
and CRGN susceptibility at Crgn1. Subsequently, we identified over-activity of the AP-1
transcription factor JunD as a cause of enhanced macrophage oxygen burst activity as well
as iNOS synthesis and WKY susceptibility to CRGN at Crgn2 8. Recently we generated a
double congenic rat strain where both Crgn1 and Crgn2 from NTN-resistant LEW rats were
introgressed into the genetic background of the WKY rat 10. Our results show that Crgn1
and Crgn2 have an additive protective effect against glomerular crescent formation 10.
However, this study also highlighted the effects of Crgn3-7, as bone marrow transplantation
experiments showed that the double congenic line shows residual susceptibility to CRGN,
which is mainly attributable to macrophage activation rather than macrophage number 10.
The aim of this study was to compare macrophage gene expression between the CRGN-
susceptible WKY and CRGN-resistant LEW strains to identify genes that reside on effector
pathways for macrophage-mediated damage to glomeruli in WKY rats. To achieve this aim
we used rat exon arrays, in basal (unstimulated) and LPS-stimulated macrophages. Our
results revealed extensive strain differences in macrophage gene expression, identified
several differentially expressed genes that positionally map to Crgn3-7 (primary effector
candidates), as well as a subset of genes, that although they map outside the known CRGN
QTL regions, showed highly significant differential expression between WKY and LEW
macrophages, before and after LPS stimulation. We also identified a small number of
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alternative splicing events that cause transcript isoform differences between macrophages
from the two strains.
Results
Differential gene expression between WKY and LEW macrophages
Exon array analysis identified 800 transcripts that were differentially expressed between
WKY and LEW bone marrow-derived macrophages, in the basal state, with a 5% false
discovery rate (FDR) threshold (Supplementary Table S1). 52.9% of these transcripts
showed higher expression in WKY compared to LEW. Notably, a subset of 19 genes
showed very strong differential expression in basal conditions (>5 fold change, <1% FDR)
(Table 1). Following LPS stimulation, 887 transcripts were differentially expressed
(Supplementary Table S2), and 60.0% of these showed higher expression in WKY
compared to LEW. There was an overlap of exactly 400 genes between the basal and LPS
conditions, while 487 genes were differentially expressed between the two strains only after
LPS stimulation. In addition, 15 genes showed very strong macrophage gene differential
expression (>5 fold change, <1% FDR) between the two strains following LPS stimulation
(Table 2). Eleven of these genes (Arg1, Fcgr3-rs, Grit, Igf2bp1, IMAGE:5598800, Lilrb3l,
Ly49si1, Ly49si2, Mmp7, Orl1684 and Pirb) showed similarly strong differential expression
in both the basal and LPS-stimulated state.
Validation of differentially expressed genes
Sixty-one of the genes showing differential expression (<5% FDR) between WKY and LEW
in basal macrophages and 68 genes showing differential expression in LPS-stimulated
macrophages mapped within the 1.5-LOD support interval of our previously localised
crescentic glomerulonephritis susceptibility QTLs (Crgn3-7) 3 (Table 3). Because these
genes are differentially expressed and map to a known QTL, they can be considered as
candidate genes for Crgn3-7 that may confer primary susceptibility to CRGN. Thirty-two of
these genes showed similarly strong differential expression in both the basal and LPS-
stimulated state. To test the accuracy of the microarray results, we randomly selected six
genes (Aig1, Csf1, Epsti1, Mcoln3, Spata6 and Stxbp5) and carried out quantitative real-
time PCR (qPCR) on these six differentially expressed transcripts (Figure 1A). With the
exception of Csf1, the differences in gene expression shown by the microarray were
confirmed for all of these genes.
In addition to the sixty-one genes that map to CRGN QTL regions, a large number of genes
(739 transcripts) that were differentially expressed (<5% FDR) between WKY and LEW
basal macrophages, do not map to previously localised CRGN QTLs. Although these genes
are not primary positional candidates for the Crgn3-7 QTLs, they may contribute indirectly
to the effector pathways that lead to WKY susceptibility to CRGN. To separate these genes
from the Crgn3-7 positional candidates, we refer to these 739 transcripts as “secondary
effector” genes. To validate these results, we selected a set of 18 of these genes for analysis
by qPCR. Eight of the 18 genes (Arg1, Ca5b, Ccl9, Igf2bp1, Lilrb3l, Mmp7, Pirb and
Trpc6) were selected because they were amongst the 19 genes that show profound
differences in expression (>5 fold change, <1% FDR) between WKY and LEW basal
macrophages, while the remaining ten (Agmat, Ccl6, Ccrl2, Cd4, Cd55, Ifngr1, Il18, Il1rn,
P2rx7, and Trf) were selected based on literature searches, as having known or suspected
links to glomerulonephritis. Consistent with the microarray results, qPCR showed that all
eighteen genes were significantly differentially expressed between WKY and LEW
macrophages and matched the directional change of the microarray data (Figure 1 B and C).
Two of the genes Agmat and Arg1 showed more than 50 fold greater expression by qPCR
analysis in WKY compared to LEW. Conversely, three genes Mmp7, Lilrb3l and Trpc6
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were expressed at over 20-fold higher levels in LEW compared to WKY macrophages. To
ensure that the strong differential expression detected by qPCR for Agmat, Arg1 and Mmp7
(the three most strongly differentially expressed genes) is not an artefact due to genomic
sequence variation, we sequenced the qPCR primer binding regions by capillary sequencing
and found no SNPs in the WKY or LEW rat strains that were able to affect the binding
properties of the primers used for qPCR amplification. Overall, therefore, we successfully
validated 23 out of the 24 transcripts selected on the basis that they either i) map to Crgn3-7,
ii) showed marked inter-strain differential expression, or iii) have previously reported links
to glomerular inflammation.
Testing for influence of Crgn1 and Crgn2 on selected gene expression
To establish whether differential expression of these genes was under the genetic control of
our previously identified QTL genes at Crgn1 and Crgn2, we measured the expression of the
23 validated selected genes in a panel of congenic strains. The panel of congenic strains
consisted of: congenic rats WKY.LCrgn1 and WKY.LCrgn2, in which we previously
introgressed the Crgn1 or Crgn2 QTL region from the resistant LEW strain into the WKY
genetic background 8,10; a reciprocal congenic strain on the Lewis background for Crgn1
(LEW.WCrgn1); and a double congenic strain (WKY.LCrgn1,2) where both Crgn loci from
the resistant LEW strain were introgressed into the WKY genetic background. The
expression levels in the macrophages of the congenic animals matched those of the genetic
background parental strain for all genes, indicating that they are not influenced in trans by
genes encoded at Crgn1 and/or Crgn2 (Figure 2). Most significantly our data shows that
none of the five validated positional candidate genes at Crgn3-7 are influenced by Crgn1 or
Crgn2.
Pathway and functional annotation analysis
To characterise functionally the sets of genes that were differentially expressed between
WKY and LEW macrophages, we performed pathway and functional annotation analysis
using the DAVID Bioinformatics Resources 11,12. We used the lists of 800 and 887 genes
that were differentially expressed between WKY and LEW macrophages before and after
LPS stimulation respectively (<5% FDR) and found five KEGG (Kyoto Encyclopedia of
Genes and Genomes) or PANTHER (Protein ANalysis THrough Evolutionary
Relationships) pathways that were enriched (EASE score < 0.01) in basal macrophages and
four pathways that were enriched in LPS-stimulated macrophages (Table 4). These results
suggest that differential gene expression between the two strains may be functionally related
to altered endocytosis, regulation of the actin cytoskeleton, leukocyte transendothelial
migration and Fc gamma receptor mediated phagocytosis. Furthermore, we identified 33
Biological Process annotation terms, that were significantly enriched (Benjamini correction
< 0.05) in basal macrophages and five Biological Process annotation terms, that were
significantly enriched in LPS-stimulated macrophages (Table 5). These results provide
strong evidence that the differences in gene expression between WKY and LEW (before and
after LPS stimulation) are likely to impact on regulation of macrophage activation, as the top
functional annotation terms, in both basal and LPS-stimulated macrophages, are cell
activation and leukocyte or lymphocyte activation.
Alternative splicing analysis between WKY and LEW macrophages
Affymetrix exon arrays allow the detection of splicing differences in two groups of data. We
initially used the intersect of three commonly used alternative splicing detection algorithms
(MiDAS, Rank Product of Slice Index and Alternative Splice ANOVA) and found 154 and
94 transcripts with isoform differences between WKY and LEW for basal or LPS-stimulated
macrophages, respectively. However, capillary sequencing of the probe-set regions of 7
selected transcripts that showed evidence of alternative exon use (Akr7a2, Coq10b, Cxcl10,
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Pa2g4, Pttg1ip, Reps2 and Slfn3), revealed that all 7 selected transcripts contained SNPs
within the probe-binding sequence of the exon that was predicted to be alternatively spliced
(Supplementary Table S3). This suggested that the set of transcripts showing apparent
alternative splicing contained a high number of false positives, due to SNPs affecting the
hybridisation properties of the corresponding probe-sets. We therefore carried out a more in
depth analysis of the data at probe level, permitting us to remove SNP containing probe-sets,
by using a filter that marks probe-sets as false positives when not all four probes within a
probe-set are differentially expressed between the two rat strains. Our revised analysis
identified a much smaller number of potentially alternatively spliced genes. Four transcripts
(Dnm3, Hes1, Ndrg4 and Rtel1) showed isoform differences between WKY and LEW
macrophages in the basal state, and four transcripts (Mical2, Polr1a, Sgms1 and Ube3a)
showed isoform differences following LPS stimulation (Table 6). None of these transcripts
show a single internal exon that is included or excluded in a strain specific pattern. Rather,
the isoform differences that we detect concern differential expression of probe-sets mapping
to the 5′ or 3′ UTR of a gene, or multiple consecutive exons of a transcript. To validate
these data, we selected two transcripts (Dmn3 and Sgms1), sequenced their differentially
expressed exons and confirmed that they did not contain any SNPs. Next we used qPCR to
test whether specific isoforms of the two selected transcripts are differentially expressed
between WKY and LEW macrophages. We used pairs of primers to amplify the exons
showing differential expression between strains (Dnm3 exon 20, and Sgms1 exon 10) and
compared the results to a second control pair of primers designed to amplify exons showing
similar expression levels between the two strains (Dnm3 exons 15-16 and Sgms1 exons
3-4). Our data confirms the microarray data predictions for i) Dnm3 where differential
expression between strains was found for exon 20, while no differential expression was
detected for exons 15 and 16; and ii) Sgms1 where differential expression between strains
was found for exon 10, while no differential expression was detected for exons 3 and 4
(Figure 3). In summary, although our analysis has revealed a high number of polymorphisms
between the two strains that account for the majority of transcripts showing apparent
splicing differences, we also identified a small number of alternatively spliced transcripts
that are differentially expressed between WKY and LEW macrophages.
Discussion
The aim of this study was to identify differentially expressed macrophage genes that reside
on effector pathways for macrophage-mediated damage to glomeruli following CRGN
induction in WKY rats. To achieve this aim, we compared gene expression in basal and
LPS-stimulated bone marrow-derived macrophages between CRGN-susceptible WKY and
CRGN-resistant LEW inbred rat strains using rat exon arrays that provide extensive
coverage of the rat genome. We used LPS stimulation because LPS, an outer membrane
component of Gram-negative bacteria, is widely used as an in vitro stimulus that mirrors
pro-inflammatory macrophage activation. Our results reveal extensive strain differences in
macrophage gene expression, with several genes that reside within Crgn3-7 showing major
expression differences, as well as a subset of genes that, although they map outside the
known CRGN QTL regions, also show highly significant differential expression between
WKY vs. LEW macrophages, before and after LPS stimulation.
We found 61 genes, differentially expressed between WKY and LEW in basal macrophages
and 68 genes differentially expressed in LPS-stimulated macrophages, which map within
our previously localised CRGN QTLs Crgn3-7. Most of these genes are novel candidates as
they have not been previously identified to have a role in renal disease. We validated the
microarray results by an independent assay, for five out of six selected genes (Aig1, Epsti1,
Mcoln3, Spata6 and Stxbp5). Analysis in congenic strains showed that none of these five
genes appear to be influenced by Crgn1 or Crgn2. Therefore, as these five genes both are
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differentially expressed and map to a CRGN susceptibility locus, they can be considered as
attractive differentially expressed positional candidate genes for glomerulonephritis
susceptibility encoded at Crgn3-7. The potential role of these genes, Aig1 (an androgen
inducible gene), Epsti1 (an epithelial-stromal interaction protein), Mcoln3 (an inward
rectifying cation channel), Spata6 (a spermatogenesis associated gene) and Stxbp5 (a
syntaxin-binding protein implicated in the formation of complexes involved in
neurotransmitter release), in macrophage function is currently unknown.
This study has identified a number of differentially expressed genes for Crgn3-7. However,
it should be noted that one or more of these QTLs may account for genetic susceptibility
mediated by intrinsic rather than circulating factors. In our recently published research
aiming to dissect the contribution of Crgn3-7 to susceptibility to CRGN in the WKY rat, we
performed bone marrow transplantation experiments between congenic and parental rats 10.
Specifically, when Lewis bone marrow is transplanted to a WKY rat, this leads to an almost
90% protection in the glomerular crescent formation following glomerulonephritis
induction. These results suggest that a residual 10 % of the CRGN susceptibility may be due
to intrinsic cell activation in the glomerulus. As this current work focused on circulating
cells, candidates for intrinsic factor CRGN susceptibility are not detectable via this screen.
We found 11 genes (Arg1, Fcgr3-rs, Grit, Igf2bp1, IMAGE:5598800, Lilrb3l, Ly49si1,
Ly49si2, Mmp7, Orl1684 and Pirb) that showed profound differences in expression between
the two strains (>5-fold change, <1% FDR), for both basal and LPS-stimulated
macrophages. Aside from Fcgr3-rs, the remaining 10 genes do not map to previously
identified CRGN QTL regions, although they show significant differential expression both
between WKY and LEW macrophages in the basal state and after LPS stimulation. These 10
genes may therefore play a significant role in differential regulation of macrophage
activation between WKY and LEW rats and may have a secondary effector role in
mediating CRGN susceptibility. Of these 10 genes, Arg1, Mmp7 and Pirb have been
identified in other studies as having potential roles in macrophage function or
glomerulonephritis. Particularly, Arg1 competes for substrate with inducible nitric oxide
synthase (iNOS) (encoded by Nos2) an enzyme that controls the production of nitric oxide
(NO), and this can prevent NO-mediated apoptosis in activated macrophages 13,14. In
addition to a primary role in macrophage function, Arg1 has been implicated in having a
role in glomerulonephritis, as up-regulation of this gene has previously been shown to occur
in macrophages and glomeruli isolated from rats following induction of acute immune
complex glomerulonephritis 15-18. We found Arg1 to be markedly over-expressed in WKY
compared to LEW basal macrophages. Mmp7 (also referred to as matrilysin) is a secreted
protease, which is important for mediating proteolytic release of tumor nercrosis factor from
macrophages 19 as well as the activation of anti-pathogenic and chemotactic proteins such as
defensins (reviewed by Burke 20). Macrophage-produced Mmp-7 has also been shown to be
necessary for macrophage infiltration 21. We found this gene to be highly under-expressed in
WKY compared to LEW basal macrophages. Pirb (also known as Lilrb3) is a receptor
expressed on immune cells where it binds to MHC class I molecules on antigen-presenting
cells and transduces a negative signal that inhibits stimulation of an immune response
(reviewed by Takai 22). We found this gene to be down-regulated in WKY compared to
LEW, and studies from Pirb-deficient mice have shown that its absence in macrophages
causes increased macrophage infiltration and affects integrin signaling 23.
Both of our previously identified Crgn1 and Crgn2 genes 3;8 were detected as significantly
differentially expressed (<5% FDR) by this study. The molecular basis for Crgn1 is a
deletion within Fcgr3-rs which abolishes the expression of this gene in WKY macrophages.
Such disruptions in gene expression are easily detected by microarrays and Fcgr3-rs was
found to be amongst the 11 genes that showed profound differences in expression between
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WKY and LEW (>5-fold change, <1% FDR), for both basal and LPS-stimulated
macrophages. The molecular basis for Crgn2 is over-expression of JunD in WKY rats
caused at least in part by a promoter polymorphism. This gene was detected by the exon
microarray as having modest (1.42 fold) yet highly significant (p = 3.5e−4; < 5% FDR)
differences in macrophages gene expression between the two strains. We find that the
differences in expression for this gene are detected more easily when qPCR is used, where
over 4 fold relative gene expression changes are detected between WKY and LEW basal
macrophages 8. Compared to quantitative PCR based methods microarrays may show a
compression of measured fold changes 24, which could have led to missing subtle
differences between transcripts if the data was filtered according to fold change. However,
our data analysis is not based on fold change filtering, but based on use of statistical tests
(ANOVA) together with false-discovery rate correction.
Our previous work has showed that WKY macrophages are primed for an inflammatory
response and show a number of phenotypic differences relating to macrophage activation
compared with those from LEW rats, including enhanced antibody-dependent cytotoxicity,
Fc receptor-mediated phagocytosis and Fc-receptor-dependent oxidative burst, as well as
increased inducible nitric oxide synthase gene (Nos2) expression upon lipopolysaccharide
(LPS) stimulation 3,8. Our functional annotation and pathway analysis supports these results,
because the canonical pathways which associate with the inter-strain differential expression
in basal and LPS-stimulated macrophages also relate to macrophage activation. For
example, Fc receptor-mediated phagocytosis is widely used as one of the measures of
macrophage activation. The canonical pathways which associate with the inter-strain
differential expression in basal and LPS-stimulated macrophages are also connected.
Specifically, phagocytosis is a specific form of endocytosis, while remodelling of the actin
cytoskeleton is both an integral part of Fc gamma receptor-mediated phagocytosis 25, as well
as being important for macrophage migration 26. Dysregulation of Fc gamma receptors is
known to associate with glomerulonephritis susceptibility both in WKY rats and in humans
(3,27,28). Therefore, some of the differentially expressed genes that associate with the above
connected pathways may represent novel targets for therapeutic intervention in nephritis.
RNA splicing is an important mechanism for generating transcriptional diversity and
regulating gene expression. We used alternative splicing analysis to identify a total of 8
genes with alternatively spliced isoforms differentially expressed between WKY and LEW,
in basal (Dnm3, Hes1, Ndrg4 and Rtel1) or LPS-stimulated macrophages (Mical2, Polr1a,
Sgms1 and Ube3a). None of these genes map to our previously localised CRGN QTLs and
their role in macrophage function is currently unknown. However, Dnm3, a dynamin
GTPase, has been implicated in phagocytosis 29, while Sgms1, a key component of lipid
rafts, is involved in T cell receptor signalling and T cell activation 30. These genes may
merit further investigation as regulators of activity in macrophages from the WKY or other
rat strains. It is interesting that the inter-strain alternative splicing differences detected by
this study were dependant on the activation state of the macrophages. Following our
stringent alternative splicing detection analysis, the four differentially alternatively spliced
transcripts in basal state did not show any inter-strain difference following the LPS
treatment. This was also the case for the four differentially alternatively spliced transcripts
in LPS-treated macrophages as the differences were no longer observed in basal conditions.
Our results therefore suggest treatment-specific alternative splicing differences in rat
BMDMs.
Our alternative splicing analysis also revealed that there are a high number of
polymorphisms between the WKY and LEW strains, which affect the hybridisation
properties of probe-sets and lead to the appearance in the microarray data of alternatively
spliced transcripts. We resolved this difficulty by analysing the data at the probe, rather than
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the conventionally used probe-set level, together with a filter that marks probe-sets as false
positives when not all four probes within a probe-set are differentially expressed between
the two rat strains. The problem of SNPs resulting in the appearance of false positive
alternative splicing events has been noticed before 31,32. In humans, data from the 1000
Genomes Project has allowed production of a list of all the SNP-containing probe-sets in the
Affymetrix Gene Chip Human Exon 1.0 ST array, which can now be masked 33,33.
Similarly, full sequencing of the WKY and LEW genomes will be needed to identify
definitively and exclude all SNP-containing probe-sets from the rat exon array.
In summary our findings reveal distinct macrophage transcriptome profiles between two rat
strains that differ in susceptibility to glomerulonephritis. We have detected novel positional
candidate genes for the CRGN susceptibility loci Crgn3-7 and identified highly
differentially expressed genes that may play a part in regulation of macrophage activity.
Many of these genes have not previously been implicated in CRGN and represent novel
candidate disease susceptibility genes and potential targets for therapeutic intervention in
immunologically-mediated glomerulonephritis.
Materials and Methods
Animals
Wistar-Kyoto (WKY/NCrl, designated here as WKY) and Lewis (LEW/Crl, designated here
as LEW) rats were purchased from Charles River (Margate, UK). All procedures were
performed in accordance with the United Kingdom Animals (Scientific Procedures) Act.
Bone marrow collection and macrophage cell culture
Femurs from adult (8-10 weeks) WKY and Lewis rats were isolated and flushed with Hanks
buffer (Invitrogen, Paisley, UK). Total BM-derived cells were plated and cultured for 6 days
in DMEM (Invitrogen) containing 25 mM HEPES (Sigma, Dorset, UK), 25% L929
conditioned medium, 25% decomplemented FBS (Biosera, Ringmer, UK), penicillin (100
U/ml; Invitrogen), streptomycin (100 μg/ml; Invitrogen), and L-glutamine (2 mM;
Invitrogen). These cells were characterized as macrophages by immunohistochemistry for
CD68 (Supplementary Figure S1). BMDMs were cultured in serum/antibiotic-free HBSS
(Invitrogen) for 16 hours. Next, cells were split into two groups of 1 × 106 cells each and
cultured for a further 24 hours in the presence/absence of 10ng/ml lipopolysachharide (LPS)
(Sigma). Cells were finally homogenized in TRIzol (Invitrogen) and stored at −70°C.
RNA Extraction, array hybridization and data analysis
Total RNA was extracted, labeled and hybridized to Gene Chip Rat Exon 1.0 ST Arrays
(Affymetrix, Santa Clara, CA, USA) as previously described 34. Four BMDM preparations,
each generated from a single animal (biological replicates), were used for each condition.
The microarray data is available in MIAME-compliant (minimum information about a
microarray experiment) format at the ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) 35 under accession code E-MEXP-2624. CEL intensity files were produced
using GeneChip Operating Software version 1.4 (Affymetrix) and quality tested using the
Affymetrix Expression Console. All 16 files were deemed suitable for further study. Probe-
level data were normalized using Robust Multi-array Average (RMA) 36. Detection of
differential expression at the gene level was performed in Partek Genomics Suite 6.4 (Partek
Incorporated, St.Louis, MO, USA) using transcripts with “extended” annotations. Data was
summarized at the gene level using a One-Step Tukey’s Biweight Algorithm, which reduces
the effect of outlier probe-sets (Statistical Algorithms Description Document; Affymetrix-
White-Paper). An ANOVA model, using strain, condition and batch as co-factors, was used
to generate raw p-values, while step-up FDR 37 was used for multiple test corrections.
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Interval estimates of QTL location
To calculate 1.5-LOD support interval estimates, data from the original genome screen for
NTN susceptibility loci in F2 rats 3 was re-analysed using the CRAN package R/qtlbim
v1.9.4 38.
Functional Association Analysis
Lists of differentially expressed genes were uploaded into The Database for Annotation,
Visualization and Integrated Discovery v6.7 (DAVID; http://david.abcc.ncifcrf.gov/) 11,12 to
determine differentially regulated pathways using the full rat genome as reference
background. Data were analyzed with the “Functional Annotation Chart” tool using KEGG
and PANTHER pathways or the Biological Process (BP) Gene Ontology (GO) FAT set
term. Cut off criteria used were either a Benjamini multiple testing correction p-value less
than 0.05, or an EASE score p-value of less than 0.01. EASE score is a modified Fisher’s
exact test 39, and it is the default test used by DAVID to identify statistical significance for
functional association analysis.
Quantitative PCR
Primers used are listed in Supplementary Table S4. PCRs were performed with an ABI 7900
Sequence Detection System (Applied Biosystems, Warrington, UK). Macrophage
quantitative real-time PCRs (qPCRs) were performed using a two-step protocol starting with
cDNA synthesis using Cells-to-cDNA II (Applied Biosystems/Ambion, Austin, TX, USA),
followed by PCR using SYBR Green Jumpstart Taq Ready mix (Sigma). A total of 10ng of
cDNA per sample was used. After an initial denaturation step (94°C for 2min), samples
were cycled 40 times at 94°C for 15 s, 60°C for 1 min and 72°C for 1min. All samples were
amplified using an independent set of biological duplicates with three technical replicates
per sample. The 7900 Fast system SDS software (Applied Biosystems) was used to obtain
CT values. Results were analysed using the comparative CT method 40. Each sample was
normalized to the reference gene Hprt, to account for cDNA loading differences.
Alternative Splicing Analysis
The Robust Multi-array Analysis (RMA) 36 algorithm was used for probe-set (exon-level)
intensity analysis. Detection of alternative splicing events was performed using three
parallel approaches: 1) Microarray Detection of Alternative Splicing (MiDAS) (Alternative
Transcript Analysis Methods for Exon Arrays; Affymetrix-White-Paper) was calculated
using the Bioconductor v2.4 41 package OneChannelGUI v1.4.5 42; 2) Rank Product of
Splice Index 43 (100 permutations) was calculated also using OneChannelGUI v1.4.5 42; 3)
An Alternative Splice ANOVA model was applied using Partek Genomics Suite v6.4
(Partek Incorporated) together with a filter to select for probe-sets showing significant
alternative splicing score determined at a 5% False Discovery Rate (FDR) 37. Next,
transcripts predicted to be alternatively spliced using an intersect of the above three
approaches, were filtered to remove data in which apparent alternative use of exons was
most likely due to single nucleotide polymorphisms (SNPs) within the probe-binding
regions. For this filter, data was analysed at the probe level, as follows: Affymetrix perfect
match (pm) probe intensities were measured using Affymetrix Power Tools version
apt-1.12.0 (http://www.affymetrix.com/partners_programs/programs/developer/tools/
powertools.affx#1_1). The data obtained were imported on to R statistical tools version
2.11.0 and subjected to quantiles normalization using the Bioconductor package
preprocessCore version 1.8 44. The normalized probe intensities were mapped to the
Affymetrix transcript annotation (NetAffx release 28). Probes were median summarized for
the four biological replicates and the respective medians from both strains were subtracted
and squared. The values obtained were subjected to the empirical fluctuation test based on
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moving sum estimate (MOSUM) implemented in R package strucchange version 1.4-0 45. P-
values less than 0.1 suggested that a transcript contained SNPs and was a false positive for
alternative splicing. Such transcripts were filtered out. Finally, all results were subjected to
manual analysis using the Partek gene view plots as well as probe-level expression signal
plots to remove false positives that had escaped the different analytical filtering steps.
Sequencing
WKY and LEW genomic DNA was isolated using a standard protocol. PCR was performed
using KOD DNA polymerse (Merk Chemicals Ltd, Nottingham, UK) with primers listed in
Supplementary Table S5. The amplified products were run on a 4% agarose gel. Bands were
extracted and purified using a QIAquick Gel Extraction Kit (Qiagen, Crawley, UK).
Samples were Cycle Sequenced using BigDye v3.1 (Applied Biosystems) chemistry with an
ABI 3730 capillary- sequencer (Applied Biosystems). Alignment was performed in
Sequencher v4.9 (Gene Codes Corporation, Ann Arbor, MI, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Validation of microarray data with quantitative PCR of selected differentially
expressed genes
A) positional differentially expressed QTL candidate genes; B and C) secondary effector
genes. Relative gene expression was compared to Hprt for WKY and LEW basal
macrophages. The secondary effector genes are presented in two separate graphs (B, C)
according to scale of relative gene expression. All samples were amplified using an
independent set of biological duplicates with three technical replicates per sample. * = p <
0.05 using a Mann-Whitney non-parametric test (one-tailed). Error bars represent standard
deviation.
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Figure 2. Selected gene expression in a panel of congenic strains
Relative gene expression compared to Hprt for WKY, LEW, WKY.LCrgn1, LEW.WCrgn1,
WKY.LCrgn2, and WKY.LCrgn1,2 in basal macrophages. The sample order shown in the
top row of graphs is maintained for all subsequent graphs. All samples were amplified using
an independent set of biological duplicates with three technical replicates per sample. * = p
< 0.05 **P < 0.01, ***P < 0.001 statistically significantly different to WKY, using a one-
way ANOVA with Bonferonni’s correction. Error bars represent standard deviation.
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Figure 3. Comparison of alternative splicing microarray data predictions with quantitative PCR
of selected transcript isoforms
A) Microarray data showing increased expression of probe-sets that correspond to Dnm3
exons 17-21, in WKY basal macrophages and increased expression of probe-sets that
correspond to Sgms1 exons 8-10, for WKY LPS-stimulated macrophages. Data is illustrated
as a gene view plot showing mean log2 signal probe-set intensities by strain. Error bars
represent standard errors. B) qPCR data confirming the microarray predictions. Relative
expression, compared to Hprt, for WKY and LEW basal macrophages of Dnm3 exon 20 and
control exons 15-16, together with WKY and LEW LPS-stimulated macrophages of Sgms1
exon 10 and control exons 3-4. All samples were amplified using an independent set of
biological duplicates with three technical replicates per sample. ***P < 0.001, using a one-
way ANOVA with Bonferonni’s correction. Error bars represent standard deviation.
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Table 5
Enrichment of functional annotation terms using DAVID for genes differentially expressed between Lewis
and WKY macrophages, with values less than 0.05 after Benjamini multiple testing correction
BP_FAT GO Term Genes (n) p-value Benjamini
Basal macrophages
GO:0001775~cell activation 29 6.13E-07 1.80E-03
GO:0045321~leukocyte activation 26 1.89E-06 2.78E-03
GO:0002250~adaptive immune response 14 2.07E-06 2.03E-03
GO:0002460~adaptive immune response based on somatic
recombination of immune receptors built from immunoglobulin
superfamily domains 14 2.07E-06 2.03E-03
GO:0046649~lymphocyte activation 22 4.66E-06 3.43E-03
GO:0010033~response to organic substance 67 5.20E-06 3.06E-03
GO:0006955~immune response 38 6.04E-06 2.96E-03
GO:0043067~regulation of programmed cell death 52 2.13E-05 8.93E-03
GO:0010941~regulation of cell death 52 2.40E-05 8.78E-03
GO:0002684~positive regulation of immune system process 25 2.63E-05 8.56E-03
GO:0002443~leukocyte mediated immunity 13 4.64E-05 1.36E-02
GO:0051338~regulation of transferase activity 28 9.21E-05 2.44E-02
GO:0001666~response to hypoxia 21 1.03E-04 2.50E-02
GO:0043549~regulation of kinase activity 27 1.05E-04 2.35E-02
GO:0030155~regulation of cell adhesion 16 1.06E-04 2.20E-02
GO:0045859~regulation of protein kinase activity 26 1.19E-04 2.31E-02
GO:0042981~regulation of apoptosis 49 1.22E-04 2.21E-02
GO:0001816~cytokine production 10 1.39E-04 2.37E-02
GO:0048871~multicellular organismal homeostasis 13 1.44E-04 2.32E-02
GO:0042127~regulation of cell proliferation 48 1.55E-04 2.38E-02
GO:0002449~lymphocyte mediated immunity 11 1.61E-04 2.34E-02
GO:0042110~T cell activation 15 1.79E-04 2.48E-02
GO:0051174~regulation of phosphorus metabolic process 34 1.85E-04 2.44E-02
GO:0019220~regulation of phosphate metabolic process 34 1.85E-04 2.44E-02
GO:0050778~positive regulation of immune response 17 2.00E-04 2.52E-02
GO:0070482~response to oxygen levels 21 2.37E-04 2.86E-02
GO:0009611~response to wounding 34 2.78E-04 3.22E-02
GO:0051347~positive regulation of transferase activity 21 3.27E-04 3.64E-02
GO:0002252~immune effector process 15 4.03E-04 4.30E-02
GO:0042592~homeostatic process 49 4.25E-04 4.37E-02
GO:0042325~regulation of phosphorylation 32 4.42E-04 4.39E-02
GO:0033674~positive regulation of kinase activity 20 5.00E-04 4.79E-02
GO:0048584~positive regulation of response to stimulus 22 5.27E-04 4.89E-02
LPS stimulated macrophages
GO:0001775~cell activation 30 2.01E-06 5.87E-03
GO:0046649~lymphocyte activation 23 8.36E-06 1.21E-02
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BP_FAT GO Term Genes (n) p-value Benjamini
GO:0045321~leukocyte activation 26 1.46E-05 1.41E-02
GO:0048872~homeostasis of number of cells 17 2.15E-05 1.56E-02
GO:0006955~immune response 38 7.69E-05 4.40E-02
BP_FAT - subset of Biological Process Gene Ontology (GO) terms, generated by the DAVID team. This subset is missing the broadest GO terms
for ease of data interpretation; p value - modified Fisher’s exact test (EASE score); Benjamini - Benjamini multiple testing correction value.
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